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PAtherosclerosis
leiotropic Effects of Statins:
enefit Beyond Cholesterol Reduction?
Meta-Regression Analysis
ennifer G. Robinson, MD, MPH,* Brian Smith, MS, PHD,† Nidhi Maheshwari, MBBS,*
elmut Schrott, MD*
owa City, Iowa
OBJECTIVES This study sought to determine whether statins reduce coronary heart disease (CHD) risk
more than other interventions that also primarily lower low-density lipoprotein cholesterol
(LDL-C).
BACKGROUND Statins have anti-inflammatory, immunomodulatory, antithrombotic, vascular, and other
non–LDL-C-lowering effects. It is unclear whether these pleiotropic effects contribute to
cardiovascular risk reduction beyond that expected from LDL-C reduction alone.
METHODS Trials published in English language journals were retrieved by searching Medline (1966 to
October 2004), bibliographies, and the author’s reference files. Randomized, placebo-
controlled trials of interventions to primarily lower LDL-C of three or more years’ duration
in which clinical disease or death were primary outcomes were used. Information on sample
size, treatment type and duration, participant characteristics at baseline, reduction in lipids,
and outcome was independently abstracted by two authors (J.R. and N.M.) using a
standardized protocol. Data from 5 diet, 3 bile acid sequestrant, 1 surgery, and 10 statin trials,
with 81,859 participants, were included in the CHD meta-regression analysis.
RESULTS The regression lines for non-statin and statin trials were similar and consistent with a
one-to-one relationship between LDL-C lowering and CHD and stroke reduction over five
years of treatment.
CONCLUSIONS The pleiotropic effects of statins do not seem to contribute an additional cardiovascular risk
reduction benefit beyond that expected from the degree of LDL-C lowering observed in other
trials that primarily lowered LDL-C. (J Am Coll Cardiol 2005;46:1855–62) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.085American College of Cardiology Foundation
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fandomized, controlled trials of 3-hydroxy-3-methylglutaryl
oenzyme A reductase inhibitors, or statins, consistently
emonstrate 25% to 40% reductions in cardiovascular events
ith 25% to 35% reductions in low-density lipoprotein
holesterol (LDL-C). Statins have effects other than
See page 1863
DL-C lowering, and some have suggested that these pleio-
ropic effects may provide a cardiovascular benefit beyond that
xpected from LDL-C lowering alone (1,2). The non–LDL-
-lowering effects of statins include other lipid (3,4), anti-
nflammatory and immunomodulatory (5–10), antithrombotic
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yerst. She has received speaker honoraria from Bristol-Myers Squibb, Merck, and
fizer, and has served as a consultant for Bristol-Myers Squibb and Pfizer. Dr. Schrott
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stra-Zeneca, Pfizer, and Reliant Pharmaceuticals. Dr. Robinson had full access to all
ata in the study and takes responsibility for the integrity of the data and the accuracy
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Manuscript received March 9, 2005; revised manuscript received April 25, 2005,
ccepted May 15, 2005.11,12), and vascular effects (13,14), which may vary by statin
15–19). This analysis explores whether statins, individually
nd as a class, reduce cardiovascular risk more than expected for
he degree of LDL-C reduction when compared with non-
tatin approaches to lipid lowering.
ETHODS
ata were abstracted from articles reporting the results of
linical trials evaluating the effect of LDL-C lowering on
ardiovascular events. Articles were identified by a literature
earch of the Medline database (1966 to October 24, 2004),
nglish language journals, a manual search of the author’s
eference files, and reference lists of original articles, reviews,
nd meta-analyses. The literature search identified 125 ab-
tracts or full-text articles, which were reviewed to determine
hether they met the criteria for inclusion (Fig. 1). Informa-
ion on sample size, treatment type and duration, participant
haracteristics at baseline, reduction in lipids, and outcomes
as independently extracted by two authors (J.R. and N.M.)
sing a standardized protocol and reporting form. Disagree-
ents were resolved by consensus. Authors were not contacted
or additional study information.
For inclusion in the primary meta-analyses, a study must
ave met these criteria: 1) random, blinded (except for diet
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Pleiotropic Effects of Statins Meta-Analysis November 15, 2005:1855–62tudies) allocation of study participants to treatment or
ontrol group; 2) a single predominantly LDL-C-lowering
reatment was compared with placebo; 3) intervention
uration of over two years; 4) primary outcomes of the trial
ere clinical events; and 5) non-fatal myocardial infarction
MI), coronary heart disease (CHD) death, and fatal and
on-fatal ischemic stroke were primary or secondary out-
omes.
Relative risk reductions and percent change in LDL-C were
sed. In the statin trials, relative risk reductions have been
hown to be homogenous across studies of primary and
econdary prevention populations with a range of baseline
DL-C levels, although absolute risk reductions vary substan-
ially depending on baseline population risk (20,21). Similarly,
ercent change in LDL-C levels in these studies was homog-
nous across a wide range of initial cholesterol levels.
igure 1. Flow diagram and trials excluded from the primary meta-
nalysis. CHD  coronary heart disease; LDL-C  low-density lipopro-
Abbreviations and Acronyms
CHD  coronary heart disease
LDL-C  low-density lipoprotein cholesterol
MI  myocardial infarction
PROSPER  PROspective Study of Pravastatin in the
Elderly at Risk
PROVE-IT  Pravastatin or Atorvastatin Evaluation
and Infection Therapy–Thrombolysis In
Myocardial Infarction-22
TNT  Treating to New Targetst
ein cholesterol; MI  myocardial infarction; RCT  randomized con-
rolled trial.Mean intent-to-treat LDL-C and total cholesterol levels
ere generally reported at only one time point during a trial.
he mean percent LDL-C reduction was calculated from
he LDL-C level in the intent-to-treat group compared
ith the level in the placebo after one or two years of
ollow-up, depending on the data reported. Because
DL-C was not reported for the diet trials, LDL-C
eduction was estimated to be approximately 13% greater
han the total cholesterol reduction based on more recent,
arge diet intervention trials (22,23) with similar percent
otal cholesterol reductions as the older diet trials.
Because relative risks were not consistently reported
cross studies, the study-specific relative risks and associated
tandard errors were estimated from the published total
umber of subjects and incident cases in the treatment and
ontrol groups for: 1) non-fatal MI and CHD death, and 2)
atal and non-fatal ischemic stroke. These end points were
hosen as representative of hard cardiovascular end points.
oronary revascularization and unstable angina diagnoses
ere excluded because of greater temporal and regional
ariability in use and classification (24,25). With the excep-
ion of two trials (26,27), a diagnosis of definite or probable
on-fatal MI or CHD death was based on protocol-defined
riteria with blinded adjudication by an independent com-
ittee (28–40) or study investigators (41–44). The Scan-
inavian Simvastatin Survival Study (31) also included silent
Is. Because data for the separate hard CHD end points
ere not available for the Air Force/Texas Coronary Ath-
rosclerosis Prevention Study (45), the primary end point
as used, which included non-fatal and fatal MIs and
nstable angina. Only the statin trials reported non-fatal
nd fatal stroke events, which were centrally adjudicated in
blinded fashion according to clinical and imaging criteria.
tatistical methods. Separate meta-analyses were conducted
o estimate the effects of: 1) LDL-C reduction from statins
ompared with non-statin interventions (diet, bile-acid seques-
rant, and surgery) on the risk of non-fatal MI or CHD death,
nd 2) LDL-C reduction from statins on the risk of non-fatal
nd fatal stroke. A random effects model was used for the
eta-analyses. The natural log-transformed relative risk was
odeled as a linear function of the study-specific mean change
n LDL cholesterol and mean length of follow-up. Gaussian
rrors were specified for the meta-analysis model as a combi-
ation of the within-study and between-study variation. The
tudy-specific standard errors for the estimated relative risks
ere used to model the within-study variation. Between-study
ariation was estimated in the analysis. Bayesian methods were
sed to fit the random-effects meta-analysis models (46). The
ayesian approach was chosen over conventional, frequentist
pproaches because the former: 1) allows for the explicit
uantification of prior knowledge and subsequent integration
ith new empirical data, 2) provides an estimate of the
osterior distribution of all model parameters, and 3) yields
ummary statistics, such as the Bayes factor, which have
atural, clinical interpretations (47,48). In contrast, a frequen-
ist approach relies on asymptotic statistical theory to derive
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November 15, 2005:1855–62 Pleiotropic Effects of Statins Meta-Analysisnly mean and variance estimates for the model parameters,
hich are not as informative as the posterior estimates from a
ayesian analysis. Furthermore, the p value, computed in
requentist approaches, is often misinterpreted in practice and
roblematic as an inferential tool. Note that the p value is
efined as the probability of obtaining the observed data or
ore extreme, unobserved data given that the null hypothesis
s true. However, what is often desired in practice is a measure
f the probability that the null (or alternative) hypothesis is true
iven the observed data. The Bayes factor provides a way to
easure this desired probability. Specifically, this analysis
eports the Bayes factor as the probability of the published data
nder the alternative hypothesis relative to the probability
nder the null hypothesis. For this application, the null
ypothesis was that the effect of LDL-C is the same between
tatin and non-statin trials versus the alternative hypothesis
hat the effect differs between the two. To obtain the relative
robability of the alternative hypothesis given the data, one
imply multiplies the Bayes factor by the prior odds that the
lternative hypothesis is true. The prior odds represents one’s
elief that the alternative is true before any new empirical data.
n this analysis, a prior odds of unity is assumed to indicate no
rior preference for the null or alternative hypothesis. Likewise,
ague prior specifications were used for all regression parame-
ers in the Bayesian analyses. The models were fit with the
inBUGS statistical software (49), and the methods of Chib
50) were used to compute the Bayes factor.
The final regression results were examined for evidence of
one-to-one relationship between LDL-C reduction and
ercent CHD risk reduction, as suggested in the literature
51). Sensitivity analyses evaluated whether statin trials that
id not meet the inclusion criteria and were of at least two
ears’ duration showed a similar relationship between
DL-C reduction and CHD death and non-fatal MI and
troke as the included trials (17,52–66). These trials in-
luded those trials without CHD as the primary end point
e.g., angiographic or ultrasound changes were primary end
oints) or active or usual care control groups with CHD and
troke end points. Studies of 2 or more years’ duration were
ncluded because the majority of the reduction in relative
isk was achieved over 2.1 to 5 years of treatment, whereas
fter 1 year of treatment, less than one-third of the eventual
isk reduction had been achieved (67).
ESULTS
ive trials of diet (26,41–44), 3 trials of bile acid seques-
rants (27–29), 1 trial of surgery (30), and 10 trials of statin
reatment (31,32,34,36,38–40,45,68,69) met the inclusion
riteria and were included in the main analysis of the CHD
ata. Nine of the statin trials were included in the main
nalysis of the stroke data (31,32,39,40,45,69–72) (Table
). The CHD analysis included 81,859 participants, and the
troke analysis included 70,300 participants from both
rimary and secondary prevention populations. uThe Bayes factor comparing the estimated effect of LDL-C
n MI or CHD death between the statin and non-statin trials
as 7.3  106. This Bayes factor is defined in the Statistical
ethods section as the probability that the effect of LDL-C
iffers between statin and non-statin trials relative to the
robability that the effect is the same, given the published data.
hus, the value of 7.3  106 provides very strong evidence
hat there is no difference between the statin and non-statin
rials included in our analysis, assuming a prior probability
istribution that assigns equal weight to the two hypotheses.
he estimated effect of LDL-C reduction on the five-year risk
f CHD death or non-fatal MI for the combined statin and
on-statin trials is plotted, along with the associated 95%
robability interval (Fig. 2). The regression line for the statin
nd non-statin trials and the line corresponding to a one-to-
ne relationship between LDL-C reduction and CHD risk are
ot significantly different because the latter is contained within
he 95% probability interval. The 95% confidence intervals of
ll individual diet, bile acid sequestrant, surgery, and statin
rials also include the one-to-one line; trials of primary and
econdary prevention populations did not differ.
The estimated effect of LDL-C reduction on the five-
ear risk of stroke is plotted in Figure 3. The 95% proba-
ility interval for the estimated regression line for the stroke
ata also contains the line representing a one-to-one rela-
ionship between LDL-C reduction and percent risk reduc-
ion. The 95% probability intervals for the individual statin
rials with both primary and secondary prevention popula-
ions, with the exception of the PROspective Study of
ravastatin in the Elderly at Risk (PROSPER) (69) study,
lso include the one-to-one line.
The sensitivity analysis of excluded statin trials of more
han two years’ duration that did not have cardiovascular
vents as the primary end points, or that had had an active
r usual-care control group, had a CHD regression line that
id not significantly differ from the one-to-one line (not
hown). Likewise, a significant difference from the one-to-
ne line was not observed for the stroke data from the
xcluded trials (52,53,55–57,60,61,63,65,66).
OMMENT
his meta-regression analysis found that the non-statin
diet, bile acid sequestrants, and ileal bypass surgery) and
tatin interventions seemed to reduce CHD risk in a similar
anner, consistent with the one-to-one relationship with
he degree of LDL-C lowering described by the National
holesterol Education Program Adult Treatment Panel
51). These results provided no significant evidence to
uggest the pleiotropic effects of statins, either as a class or
ndividually, contributed additional CHD risk reduction
eyond that expected from the degree of LDL-C lowering
een in the non-statin trials over approximately five years.
Both statins and diet have been shown to reduce inflam-
atory markers, although by varying degrees (73–75). It is
nclear whether such changes are mediated through reduced
Table 1. Characteristics of Randomized, Controlled Cholesterol-Lowering Trials Meeting Entry Criteria for Primary Meta-Regression Analyses
Study/Type Year Intervention Population
Total,
n
Mean
Follow-Up,
yrs
Baseline
LDL-C,
Mean, mg/dl
LDL-C,
% Reduction
Non-Fatal MI/CHD,
Death, %
Reduction (95% CI)
Stroke, %
Reduction (95% CI)
Diet
London hospitals (41) 1965 Low-fat diet CHD, men only 264 3 179* 11* 3 (54 to 39)
Oslo (42) 1966 PUFA CHD, men only 458 5 200* 16* 25 (10 to 48)
MRC (43) 1968 Soy oil CHD, men only 393 4 185* 18* 16 (32 to 46)
Los Angeles (44) 1969 PUFA High-risk primary,
men only
846 5 158* 17* 17 (29 to 46)
Sydney (26) 1978 PUFA CHD, men only 458 5 192* 4* 65 (185 to 4)
Bile acid sequestrant
Upjohn (27) 1978 Colestipol Primary and CVD 2,278 3 214* 13* 38 (11 to 65)
NHLBI (28) 1984 Cholestyramine CHD 116 5 236 21 53 (44 to 85)
LRC (29) 1984 Cholestyramine Moderate-risk primary,
men only
3,806 5 216 13 17 (9 to 37)
Surgery
POSCH (30) 1998 Ileal bypass CHD 838 5 179 38 31 (1 to 53)
Statin
4S (31) 1994 Simvastatin CHD 4,444 5.4 188 35 31 (21 to 39) 29 (2 to 48)
WOSCOPS (32) 1995 Pravastatin High-risk primary,
men only
6,595 4.9 192 26 30 (15 to 43) 10 (34 to 40)
CARE (68,70) 1996 Pravastatin CHD 4,159 5 139 28 23 (7 to 36) 32 (2 to 52)
LIPID (34,71) 1998 Pravastatin CHD 9,014 6.1 150 25 22 (13 to 31) 17 (2 to 33)
AFCAPS/TexCAPS (45) 1998 Lovastatin Moderate-risk primary 6,605 5.2 150 26.5 37 (20 to 50) 90 (83 to 99)‡
HPS (36,72) 2002 Simvastatin CHD, CVD, diabetes 20,536 5 131† 30 26 (19 to 32) 24 (14 to 33)
PROSPER (69) 2002 Pravastatin Elderly, primary and
CVD
5,804 3.2 147 27 17 (3 to 30) 4 (33 to 19)
ALERT (38) 2003 Fluvastatin Renal transplant,
primary, CHD and
CVD
2,102 5.1 159 32 25 (2 to 44)
ASCOT-LLA (39) 2003 Atorvastatin High-risk primary,
CVD
10,305 3.3 133 35 35 (17 to 50) 27 (4 to 45)
CARDS (40) 2004 Atorvastatin Diabetes 2,838 3.9 117 40 35 (3 to 56) 41 (2 to 66)
*LDL-C was not measured in these trials. LDL-C was estimated as approximately 68% of total cholesterol. LDL-C reduction was estimated as 14% greater than total cholesterol reduction. †Direct LDL-C measurement. LDL-C estimated
by Friedewald equation, 150 to 155 mg/dl. ‡Stroke events in the treatment group  0; standard error was calculated using stroke events  0.5.
AFCAPS/TexCAPS  Air Force/Texas Coronary Atherosclerosis Prevention Study; ALERT  Assessment of LEscol in Renal Transplantation; ASCOT-LLA  Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm;
CARDS  Collaborative Atorvastatin Diabetes Study; CARE  Cholesterol and Recurrent Events study; CHD  coronary heart disease; CI  confidence interval; CVD  other cardiovascular disease such as stroke, transient ischemic
attack, or peripheral arterial disease; 4S Scandinavian Simvastatin Survival Study; HPSHeart Protection Study; LDL-C low-density lipoprotein cholesterol; LIPID Long-term Intervention with Pravastatin in Ischaemic Disease;
LRC  Lipid Research Clinics; MI  myocardial infarction; MRC  Medical Research Council; NHLBI  National Heart, Lung, and Blood Institute; POSCH  Program on the Surgical Control of the Hyperlipidemias; primary
 primary prevention, no known CHD, CVD, or diabetes; PROSPER  PROspective Study of Pravastatin in the Elderly at Risk; PUFA  polyunsaturated fatty acids; WOSCOPS  West of Scotland Coronary Prevention Study.
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November 15, 2005:1855–62 Pleiotropic Effects of Statins Meta-Analysisipid levels or through direct anti-inflammatory actions. In
rials of atorvastatin and pravastatin in patients with acute
oronary syndromes, the degree of C-reactive protein re-
uction correlated poorly with the degree of LDL-C reduc-
ion for individual participants (76,77). In this analysis,
hich compared overall trial results, there seemed to be no
ignificant difference between the individual statins, diet,
nd other non-statin interventions independent of LDL-C
eduction, lending support to the concept that the anti-
nflammatory effects described for statins may be the result
f, rather than in addition to, LDL-C lowering. The direct
orollary of such a relationship between LDL-C lowering
nd reduced inflammation suggests that inflammation may
e a mechanism through which LDL-C promotes athero-
enesis rather than an independent effect. Indeed, experi-
ental data support a direct causal relationship between
DL-C and inflammation. Statin-induced inhibition of
holesterol synthesis has been shown to disrupt lipid rafts in
ell membranes, resulting in altered lymphocyte function
igure 2. Estimated change in the five-year relative risk of non-fatal
yocardial infarction or CHD death associated with mean LDL-C
eduction for the diet, bile-acid sequestrant, surgery, and statin trials
dashed line) along with the 95% probability interval (dotted line). The
olid line has a slope  1. The crude risk estimates from the individual
tudies are plotted along with their associated 95% confidence intervals.
he Sydney (26) trial is not shown but was included in the analysis. Statin
rials are designated by the boldface symbols. CHD  coronary heart
isease; LDL-C  low-density lipoprotein cholesterol. Study acronyms:
RC  Medical Research Council; LRC  Lipid Research Clinics;
HLBI  National Heart, Lung, and Blood Institute; POSCH 
rogram on the Surgical Control of the Hyperlipidemias; 4S  Scandi-
avian Simvastatin Survival Study; WOSCOPS  West of Scotland
oronary Prevention Study; CARE  Cholesterol and Recurrent Events
tudy; LIPID  Long-Term Intervention with Pravastatin in Ischemic
isease; AF/TexCAPS  Air Force/Texas Coronary Atherosclerosis
revention Study; HPSHeart Protection Study; ALERT Assessment
f LEscol in Renal Transplantation; PROSPER  PROspective Study of
ravastatin in the Elderly at Risk; ASCOT-LLA  Anglo-Scandinavian
ardiac Outcomes Trial–Lipid Lowering Arm; CARDS  Collaborative
torvastatin Diabetes Study.78). The alternative explanation that statins directly and
O
sndependently lower both LDL-C and inflammatory mark-
rs has not been disproved by these data, but this analysis
oes show that statins seem to be no more effective in this
egard than diet, bile acid sequestrants, or surgery.
The lack of correlation between LDL-C and a single
easure of C-reactive protein reduction in individual acute
oronary syndrome patients may be misleading. Intra-
ndividual variation of C-reactive protein values varies by
ore than 40% to 60% in patients with stable ischemic heart
isease (79). For acute coronary syndrome patients, recovery
rom the acute event, along with regression to the mean, is
ikely to add even greater measurement variability, thereby
esulting in a lack of correlation with LDL-C levels. The
nding that aggressive LDL-C reduction has been shown to
tabilize and even regress atherosclerotic plaque in some but
ot all (80,81) patients suggests a unifying explanation for
he lack of correlation between LDL-C and C-reactive
rotein. The lack of correlation between LDL-C and
-reactive protein levels may reflect plaque stabilization, or
ack thereof, within the overall atherosclerotic milieu of
he individual patient. That is, an LDL-C level 70 mg/dl
ay be sufficient to stabilize or regress plaque for one
atient, but may not be sufficient for another patient because
f cigarette smoking or poorly controlled diabetes or hyper-
ension. Indeed, in the Pravastatin or Atorvastatin Evalua-
ion and Infection Therapy–Thrombolysis In Myocardial
igure 3. Estimated change in the five-year relative risk of stroke associ-
ted with mean LDL-C reduction for the statin trials* (dashed line) along
ith the 95% probability interval (dotted line). The solid line has a slope
1. The crude risk estimates from the individual studies are plotted along
ith their associated 95% confidence intervals. LDL-C  low-density-
ipoprotein cholesterol. Study acronyms: 4S  Scandinavian Simvastatin
urvival Study; WOSCOPS  West of Scotland Coronary Prevention
tudy; CARE  Cholesterol And Recurrent Events study; LIPID 
ong-Term Intervention with Pravastatin in Ischemic Disease; HPS 
eart Protection Study; PROSPER  PROspective Study of Pravastatin
n the Elderly at Risk; ASCOT-LLA  Anglo-Scandinavian Cardiac
utcomes Trial–Lipid Lowering Arm; CARDS  Collaborative Atorva-
tatin Diabetes Study. *Only statin trials reported stroke incidence.
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Pleiotropic Effects of Statins Meta-Analysis November 15, 2005:1855–62nfarction-22 (PROVE-IT) trial, recurrent CHD event
ates were lowest in patients with LDL-C levels70 mg/dl
nd low C-reactive protein levels 1.0 mg/l (77).
Some have suggested that the pleiotropic effects of statins
ay play an important role in stabilizing vulnerable plaque
nd the very early reduction in CHD events in acute
oronary syndrome trials (17,81–83). However, in the
onger-term acute coronary syndrome trials, despite signif-
cant reductions in inflammatory markers, cumulative CHD
isk reduction did not seem to exceed that expected from the
ne-to-one relationship between LDL-C lowering and
HD risk seen in trials of stable patients. In the
ROVE-IT trial, the atorvastatin 80 mg group experienced
n additional 18% reduction in CHD events over pravasta-
in 40 mg (17). This amount of CHD risk reduction is
ctually somewhat less than would be expected from a 31%
ower LDL-C level in the atorvastatin group if a one-to-one
elationship were present. Although the trial was only two
ears long, the benefit should begin approaching that seen
y three to five years (67).
The recent Phase Z of the A to Z trial showed a
on-significant 12% reduction in non-fatal MI and CHD
eath with a 14% greater reduction in LDL-C in the early
reatment/simvastatin 40 to 80 mg group compared with
he later treatment/simvastatin 20 mg group over two years
66). Although the PROVE-IT and A to Z trials suggest
ome attenuation of CHD risk reduction may occur with
DL-C lowering beyond 35%, results from the recent
reating to New Targets (TNT) trial (84) showed further
eduction in CHD risk with more aggressive LDL-C
eduction. The five-year TNT study enrolled 10,001 men
nd women with stable CHD who were randomized to
torvastatin 10 or 80 mg. Consistent with the findings of
his analysis, the 24% lower LDL-C level in the atorvastatin
0 mg group (mean LDL-C level of 77 mg/dl) resulted in
significant 22% reduction in non-fatal MI and CHD
eath compared with the atorvastatin 10 mg group (mean
DL-C of 101 mg/dl). During the open-label lead-in
eriod of the TNT trial, LDL-C was reduced by 35% by
torvastatin 10 mg. Therefore, the absolute LDL-C reduc-
ion in the atorvastatin 80 mg group of the TNT trial was
pproximately 59%. Because a previous trial of atorvastatin
0 mg showed a 34% reduction in non-fatal MI and CHD
eath with a 40% reduction in LDL-C after four years of
reatment (40), the atorvastatin 80 mg treatment in the
NT trial may have lowered CHD risk by as much as 56%
ompared with placebo treatment. These findings seem to
xtend the one-to-one relationship between LDL-C and
HD risk reduction to more aggressive levels of LDL-C
eduction. Further confirmation awaits the results of soon-
o-be-completed large trials of aggressive LDL-C reduction
85,86).
This analysis also suggests that additive reductions in
ardiovascular risk reduction should occur when newer
on-statin agents that primarily lower LDL-C, such as
zetimibe, are added to statin therapy. Although no clinical
utcomes data are yet available for ezetimibe, the cardio-ascular risk reduction benefit with this agent would be
xpected to be in direct proportion to its degree of LDL-C
eduction (18% to 20%) (87).
Because many epidemiologic studies have shown no
elationship between total cholesterol level and stroke (88),
ome have speculated whether pleiotropic effects contribute
o the reduction in stroke risk observed in the statin trials
89). However, in a meta-analysis of cohort studies by
troke type, a 1 mmol/l (about 28%) decrease in LDL-C
as associated with a 15% reduction in ischemic stroke and
19% increase in hemorrhagic stroke (90). A slightly greater
enefit was shown in the accompanying meta-analysis of 58
andomized trials in which an approximately 20% lower
schemic stroke risk occurred with a 1 mmol/l reduction in
DL-C, similar to the results of this study. With the
xception of the PROSPER trial, the confidence intervals
or the non-fatal and fatal stroke end points included the
ne-to-one line. Several explanations for the lesser benefit
or stroke, despite a 35% reduction in LDL-C, in the
ROSPER trial have been forwarded, including a low
troke event rate in the trial (50% of expected rate) and short
uration of the trial (three years) with stroke reduction from
tatins appearing after three years, whereas CHD risk
eduction occurs earlier (69). The recent data from the TNT
rial extends the one-to-one relationship between LDL-C
nd stroke to more aggressive LDL-C reduction, with a
5% reduction in fatal and non-fatal stroke in the atorva-
tatin 80 mg group (84). Because stroke data were not
vailable from the non-statin trials, this analysis could not
xplore whether pleiotropic effects of statin treatment may
e contributing to greater reductions in stroke risk than
xpected from other LDL-C lowering interventions.
Although emerging data suggest the anti-inflammatory,
mmunomodulatory, and vascular effects of statins may play
role in the progression of other chronic diseases such as
iabetes mellitus (91) and rheumatoid arthritis (9), the
resent data do not seem to support a role for these effects
n the clinical management of cardiovascular risk. The
vidence to date supports statin choice guided by LDL-C
owering efficacy rather than non-lipid effects, as well as
ssues such as safety, drug interactions, and cost (92,93).
he focus should remain on achieving LDL-C goals as
ecommended by current guidelines (51,94). Further re-
earch is needed before the choice of cholesterol-lowering
herapy is influenced by effects other than the degree of
DL-C reduction.
eprint requests and correspondence:Dr. Jennifer G. Robinson,
00 Hawkins Drive, SE226GH, Iowa City, Iowa 52242. E-mail:
ennifer-g-robinson@uiowa.edu.
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